Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631674 | 0.81 | MAPT (0.44) | MAPTHDAC2MMP2MMP9NPC1 | |
| SCHEMBL13660683 | 0.81 | MAPT (0.44) | MAPTHDAC2MMP2MMP9NPC1 | |
| SCHEMBL1688066 | 0.80 | MCL1 (0.39) | MAPTMMP2MMP9NPC1LMNA | |
| SCHEMBL1688069 | 0.77 | FOLH1 (0.34) | MAPTLMNAFOLH1NAALAD2 | |
| SCHEMBL25454622 | 0.76 | KCNN4 (0.42) | MAPTMMP2MMP9NPC1LMNA | |
| SCHEMBL31501069 | 0.76 | MAPT (0.51) | MAPTMMP2MMP9NPC1LMNA | |
| SCHEMBL5489086 | 0.76 | CA2 (0.42) | FOLH1NAALAD2 | |
| SCHEMBL11131045 | 0.76 | CA2 (0.42) | FOLH1NAALAD2 | |
| SCHEMBL4519259 | 0.76 | CA2 (0.42) | FOLH1NAALAD2 | |
| SCHEMBL14112000 | 0.74 | MCL1 (0.40) | MMP2MMP9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2012-02-16 | — | — | US | disclosed |
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | Ironwood Pharmaceuticals Inc. | 2011-01-27 | — | — | US | disclosed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | MAPT 4803/4885HDAC2 4189/4885MMP2 3136/4885 |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | MAPT 4803/4885HDAC2 4189/4885MMP2 3136/4885 |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | FGB, F13B, SERPINC1 | MAPT 4880/4885HDAC2 768/4885MMP2 862/4885 |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | MAPT 4209/4885HDAC2 4075/4885MMP2 3478/4885 |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GIPR, VIP, GCGR | MAPT 4367/4885HDAC2 3939/4885MMP2 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.